Xeris Biopharma Q2 revenue rises 34%, slightly beats estimates
XERS•Outlook
- Xeris tightens 2026 total revenue guidance to $385 mln to $390 mln
- Company expects Recorlev investments to drive growth in H2 2026
Overview
- U.S. biopharmaceutical firm's Q2 net product revenue grew 34% yr/yr, slightly beating analyst expectations
- Company tightened full-year 2026 revenue guidance to $385–$390 mln
- All 2028 Convertible Notes eliminated, reducing debt and issuing shares
Key Details
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Product Revenue | Slight Beat* | $91.004 mln | $90.23 mln (6 Analysts) |
| Q2 Loss Per Share | $0.18 | ||
| Q2 Net Loss | $31.10 mln | ||
| Q2 Operating Income | $5.17 mln |
*Applies to a deviation of less than 1%; not applicable for per-share numbers.
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the pharmaceuticals peer group is "buy"
- Wall Street's median 12-month price target for Xeris Biopharma Holdings, Inc. is $10.00, about 23.3% above its August 5 closing price of $8.11
